论文部分内容阅读
为了观察多西他赛(泰索帝)每周给药方案和3周给药方案治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应,对112例患者,随机分为实验组(多西他赛每周组)和对照组(多西他赛3周组)。实验组:多西他赛35mg/m2,静脉滴入,d1、d8、d15;顺铂(DDP)75mg/m2,静脉滴入,d1;对照组:多西他赛75mg/m2,静脉滴入,d1;DDP80mg/m2,分3次于d1、d2、d3,静脉滴入,28d为1个周期。至少完成2个周期。结果:实验组有21例患者部分缓解,占全部入组病例的38.18%,高于对照组3周方案有效率31.58%(18/57),其中鳞癌有效率50.00%(12/24)明显好于对照组34.62%(9/26),P<0.05。Ⅲ～Ⅳ度粒细胞减少为10.09%(6/55),较对照组26.32%(15/57)明显减少,实验组体液潴留及胃肠道反应多于对照组,分别为23.64%(13/55)和12.73%(7/55),P<0.05。其他不良反应与对照组比较差异无统计学意义。初步研究结果提示,多西他赛每周给药联合DDP治疗晚期NSCLC疗效较好,骨髓毒性较轻。
In order to observe the efficacy and adverse reactions of docetaxel (Taxotere) weekly administration and 3-week dosing regimen in the treatment of advanced non-small cell lung cancer (NSCLC), 112 patients were randomly divided into experimental group His weekly group) and control group (docetaxel 3 weeks group). Experimental group: docetaxel 35mg / m2, intravenous infusion, d1, d8, d15; cisplatin (DDP) 75mg / m2, intravenous infusion, d1; control group: docetaxel 75mg / m2, intravenous infusion , d1; DDP80mg / m2, three times in d1, d2, d3, intravenous infusion, 28d for a cycle. Complete at least 2 cycles. Results: Twenty-one patients in the experimental group were partially relieved, accounting for 38.18% of all the patients in the experimental group and 31.58% (18/57) in the three-week control group. The effective rate of squamous cell carcinoma was 50.00% (12/24) 34.62% (9/26) better than the control group, P <0.05. Ⅲ ~ Ⅳ neutropenia was 10.09% (6/55), which was significantly lower than that of the control group (26.32%, 15/57). The fluid retention and gastrointestinal reactions in the experimental group were more than those in the control group (23.64%, 13 / 55) and 12.73% (7/55), P <0.05. Other adverse reactions compared with the control group no significant difference. Preliminary results suggest that docetaxel weekly combined with DDP treatment of advanced NSCLC better efficacy, less myelotoxicity.